MK 886
Alternative Names: L 663536; MK 0886Latest Information Update: 18 Feb 2008
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antiallergics; Antiasthmatics; Antineoplastics; Antipsoriatics
- Mechanism of Action 5-lipoxygenase-activating protein inhibitors; DNA synthesis inhibitors; Leukotriene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Cancer; Coronary thrombosis; Inflammatory bowel diseases; Psoriasis; Thrombosis; Transplant rejection
Most Recent Events
- 08 Sep 1998 No-Development-Reported for Coronary thrombosis in USA (unspecified route)
- 08 Sep 1998 No-Development-Reported for Thrombosis in USA (unspecified route)
- 29 Mar 1996 An animal study has been added to the Ischaemic Heart Disease pharmacodynamics section